COLL has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
COLL has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Pretax income is the income that a company earns before paying income taxes. Collegium Pharmaceutical's pretax income for the three months ended in Sep. 2024 was $15.6 Mil. Its pretax income for the trailing twelve months (TTM) ended in Sep. 2024 was $128.0 Mil. Collegium Pharmaceutical's pretax margin was 9.78%.
During the past 11 years, Collegium Pharmaceutical's highest Pretax Margin was 21.36%. The lowest was -5504.15%. And the median was -6.94%.
The historical data trend for Collegium Pharmaceutical's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Collegium Pharmaceutical Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Pre-Tax Income | Get a 7-Day Free Trial | -22.72 | 27.58 | -3.37 | -28.85 | 75.73 |
Collegium Pharmaceutical Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Pre-Tax Income | Get a 7-Day Free Trial | 28.78 | 46.71 | 36.62 | 29.10 | 15.58 |
For the Drug Manufacturers - Specialty & Generic subindustry, Collegium Pharmaceutical's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Collegium Pharmaceutical's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Collegium Pharmaceutical's Pre-Tax Income falls into.
This is the income that a company earns before paying income taxes.
Collegium Pharmaceutical's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pretax Income | = | Operating Income | + | Non Operating Income | + | Interest Expense | + | Interest Income | + | Other |
= | 166.961 | + | -23.504 | + | -83.339 | + | 15.615 | + | 0 | |
= | 75.7 |
Collegium Pharmaceutical's Pretax Income for the quarter that ended in Sep. 2024 is calculated as
Pretax Income | = | Operating Income | + | Non Operating Income | + | Interest Expense | + | Interest Income | + | Other |
= | 34.839 | + | -4.145 | + | -18.394 | + | 3.28 | + | 0 | |
= | 15.6 |
Pre-Tax Income for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $128.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Collegium Pharmaceutical (NAS:COLL) Pre-Tax Income Explanation
Collegium Pharmaceutical's Pretax Margin for the quarter that ended in Sep. 2024 is calculated as
Pretax Margin | = | Pretax Income | / | Revenue |
= | 15.58 | / | 159.301 | |
= | 9.78% |
During the past 11 years, Collegium Pharmaceutical's highest Pretax Margin was 21.36%. The lowest was -5504.15%. And the median was -6.94%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Collegium Pharmaceutical's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Thomas B Smith | officer: EVP and Chief Medical Officer | BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE SUITE 225, RALEIGH NC 27612 |
Shirley R. Kuhlmann | officer: EVP and General Counsel | 780 DEDHAM STREET, SUITE 800, CANTON MA 02021 |
Tupper Colleen | officer: EVP & Chief Financial Officer | C/O COLLEGIUM PHARMACEUTICAL, INC., 100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072 |
Scott Dreyer | officer: EVP & Chief Commercial Officer | 780 DEDHAM STREET, SUITE 800, CANTON MA 02021 |
Garen G Bohlin | director | C/O PRAECIS PHARMACEUTICALS INC, 830 WINTER STREET, WALTHAM MA 02451 |
Joseph Ciaffoni | director, officer: President and CEO | 100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072 |
Michael Thomas Heffernan | director | C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518 |
John Gordon Freund | director | 125 UNIVERSITY AVE., C/O SKYLINE VENTURES, PALO ALTO CA 94301 |
Rita J. Balice-gordon | director | C/O COLLEGIUM PHARMACEUTICAL, INC., 100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072 |
John A. Fallon | director | C/O INSULET CORPORATION, 9 OAK PARK DRIVE, BEDFORD MA 01730 |
Gwen A Melincoff | director | C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Gino Santini | director | C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451 |
Neil F. Mcfarlane | director | C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130 |
Richard Malamut | officer: EVP and Chief Medical Officer | 100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072 |
Alison B Fleming | officer: Vice President, Product Devlp | 780 DEDHAM STREET, SUITE 800, CANTON MA 02021 |
From GuruFocus
By Marketwired • 11-12-2024
By GuruFocus Research • 09-17-2024
By GuruFocus News • 11-14-2024
By GuruFocus News • 10-09-2024
By Marketwired • 09-04-2024
By Marketwired • 07-29-2024
By GuruFocus Research • 09-07-2024
By GuruFocus News • 10-11-2024
By GuruFocus Research • 08-08-2024
By Marketwired • 08-30-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.